Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hypoglycaemia in Type 2 diabetes.

S A Amiel1, T Dixon, R Mann

  • 1King's College London School of Medicine, London, UK.

Diabetic Medicine : a Journal of the British Diabetic Association
|January 25, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First Results on the Search for Lepton Number Violating Neutrinoless Double-β Decay with the LEGEND-200 Experiment.

Physical review letters·2026
Same author

Half-Life and Precision Shape Measurement of the 2νββ Decay of ^{130}Te.

Physical review letters·2025
Same author

Search for Fractionally Charged Particles with CUORE.

Physical review letters·2025
Same author

Cannabidiol versus placebo as adjunctive treatment in early psychosis: study protocol for randomized controlled trial.

Trials·2023
Same author

Measurement of the 2νββ Decay Rate and Spectral Shape of ^{100}Mo from the CUPID-Mo Experiment.

Physical review letters·2023
Same author

The effect of recreational cannabis legalization and commercialization on substance use, mental health, and injury: a systematic review.

Public health·2023
Same journal

Refining metabolic-response signals after liraglutide therapy in type 1 diabetes.

Diabetic medicine : a journal of the British Diabetic Association·2026
Same journal

Finger-stick glucose testing as an institutional stressor: Staff perspectives from long-term care.

Diabetic medicine : a journal of the British Diabetic Association·2026
Same journal

Prevalence, duration, and clinical implications of continuous glucose monitor measurement limit capping in type 1 diabetes.

Diabetic medicine : a journal of the British Diabetic Association·2026
Same journal

Disentangling the effect of brain insulin resistance on brain health (BIR-BrainHealth): Rationale and study protocol.

Diabetic medicine : a journal of the British Diabetic Association·2026
Same journal

Clinical characteristics and in-hospital mortality among insulin pump users with acute coronary syndrome in the predominantly open-loop era: A UK-wide MINAP registry analysis.

Diabetic medicine : a journal of the British Diabetic Association·2026
Same journal

Hyperlipidaemia in youth with type 1 diabetes: Are current guidelines clinically useful?

Diabetic medicine : a journal of the British Diabetic Association·2026
See all related articles

Diabetes medications like sulfonylureas (SUs) and insulin can cause hypoglycemia. Newer therapies may offer better glucose control with lower hypoglycemia risk, improving patient outcomes.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Diabetology

Background:

  • Hypoglycemia is a significant complication of Type 2 diabetes treatment, primarily caused by medications that increase insulin levels independently of blood glucose, such as sulfonylureas (SUs) and exogenous insulin.
  • Risk factors for hypoglycemia include older age, longer diabetes duration, reduced insulin reserve, and intensive glycemic control efforts.
  • Comparing hypoglycemia rates is challenging due to variations in definitions, data collection, drug regimens, and patient populations.

Purpose of the Study:

  • To analyze the causes, risks, and clinical impact of hypoglycemia in Type 2 diabetes.
  • To evaluate the comparative rates of severe hypoglycemia associated with different diabetes medications.
  • To discuss the implications of hypoglycemia on glycemic control and diabetic complications.

Related Experiment Videos

Main Methods:

  • Review of existing literature and data on hypoglycemia in Type 2 diabetes patients.
  • Analysis of reported rates of severe hypoglycemia for insulin and sulfonylurea (SU) therapies.
  • Estimation of the clinical and economic impact of severe hypoglycemic events.

Main Results:

  • Patients on insulin exhibit the highest rates of self-reported severe hypoglycemia (25% after >5 years of use).
  • Sulfonylureas (SUs) are linked to significantly lower severe hypoglycemia rates, though over 5000 UK patients annually experience severe SU-related events requiring emergency intervention.
  • Severe hypoglycemia incurs substantial costs, with hospital admissions averaging around £1000 each.

Conclusions:

  • Hypoglycemia and fear of it impede optimal glycemic control in Type 2 diabetes management.
  • Newer therapies targeting the incretin axis may present a reduced risk of hypoglycemia.
  • Prudent use of existing low-risk therapies and adoption of newer treatments could enhance long-term glucose control and decrease diabetic complication risks.